Abstract
US legislation now allows pharmaceutical brand owners to advertise prescription drugs ‘direct to consumers’ (DTC). The easy global access to manufacturers' US targeted Internet sites suggests that a change in European legislation may soon follow. Little or no research has been conducted within the EU context regarding the views of health professionals on DTC. The authors report the results of a survey, which records the differing attitudes of UK GPs and hospital doctors towards DTC advertising, and examines the issues for patient-doctor-manufacturer relationships. This study, in part, provides a UK replication of research conducted in the USA by Petroshius et al. (1995), and confirms the expected sharply contrasting attitudes to DTC between UK and US doctors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
